Trial Information

Summary: Open-Label Study of Invega for the Treatment of Mania in Children and Adolescents ages 6-17 with Bipolar I, Bipolar II, and Bipolar Spectrum Disorder

Children between the ages of 6-17 years old who have, or display symptoms of bipolar disorder (explosiveness, mood swings, irritability, or violent behavior) are asked to participate in an 8-week research study to determine the effectiveness and safety of a medication called Invega (paliperidone) in the treatment of children with bipolar disorder. After undergoing a comprehensive evaluation by medical doctors with a specialty in this area, children who are found eligible to participate in this research study will be treated with Invega and will have weekly visits for 8 weeks in an effort to closely monitor each child’s response to the medication. Eligible participants will receive study-related evaluations and weekly study visits with our study doctors at no cost.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.